On this page

Most guidance on pituitary adenoma comes from expert consensus statements by the Pituitary Society and the Endocrine Society, supported by observational studies. Different questions have different sources: a tumor found by chance, a prolactinoma, and follow-up after surgery each have their own guidance.

Tumors found by chance

The 2025 Pituitary Society consensus on incidentalomas covers hormone testing, imaging and eye assessment, and when to watch or operate1. Many of its recommendations rest on limited comparative evidence.

Prolactinoma

The 2023 Pituitary Society consensus discusses dopamine agonist medicines and surgery, and recommends that expert surgery be discussed as a first-line option for selected tumors2. A correction published in October 2023 updated one reference in its discussion of surgical remission3.

Acromegaly and Cushing disease

A 2025 consensus on acromegaly outcomes distinguishes remission after surgery from control of the disease with medicines4. A 2021 guideline update covers Cushing disease, in which a pituitary tumor drives excess cortisol, including surgery, other treatments and recurrence5.

Terminology

A 2023 workshop perspective explains the World Health Organization's 2022 change to PitNET terminology and the concern that the name could be misread as describing how a tumor behaves6. The National Cancer Institute's pages give patient-level background on pituitary tumors, their symptoms and treatment789.

Hormone replacement and follow-up

An Endocrine Society guideline covers hormone replacement in adults with hypopituitarism10. A Congress of Neurological Surgeons guideline chapter covers follow-up after treatment of nonfunctioning adenomas and notes that the best surveillance schedule is not established11.

Pituitary apoplexy

Society for Endocrinology emergency guidance describes the warning signs of pituitary apoplexy12, and a 2026 review covers its current surgical and conservative management13.

References

  1. Fleseriu M et al. Nat Rev Endocrinol. 2025;21:638–655. Published 24 June 2025. doi:10.1038/s41574-025-01134-8. Source ↩
  2. Petersenn S et al. Nat Rev Endocrinol. 2023;19:722–740. doi:10.1038/s41574-023-00886-5. Read with Author Correction, 17 October 2023. Source ↩
  3. Petersenn S et al. Author Correction. Nat Rev Endocrinol. 2024;20:62. Published online 17 October 2023. doi:10.1038/s41574-023-00916-2. Source ↩
  4. Melmed S et al. Nat Rev Endocrinol. 2025;21:718–737. doi:10.1038/s41574-025-01148-2. Source ↩
  5. Fleseriu M et al. Lancet Diabetes Endocrinol. 2021;9:847–875. doi:10.1016/S2213-8587(21)00235-7. Source ↩
  6. Ho KKY et al. Nat Rev Endocrinol. 2023. Published 17 August 2023. doi:10.1038/s41574-023-00883-8. Source ↩
  7. National Cancer Institute. What Are Pituitary Tumors? Updated 28 March 2025. Source ↩
  8. National Cancer Institute. Pituitary Tumors Signs & Symptoms. Updated 28 March 2025. Source ↩
  9. National Cancer Institute. Pituitary Tumors Treatment. Updated 28 March 2025. Source ↩
  10. Endocrine Society. Hormonal Replacement in Hypopituitarism in Adults: Clinical Practice Guideline. 2016. Source ↩
  11. Congress of Neurological Surgeons. Management of Nonfunctioning Pituitary Adenomas, chapter 8: Post Treatment Follow-up Evaluation. 2016. Source ↩
  12. Baldeweg SE et al. Society for Endocrinology Endocrine Emergency Guidance. Endocr Connect. 2016;5:G12–G15. doi:10.1530/EC-16-0057. Source ↩
  13. Biagetti B et al. Eur J Endocrinol. 2026;194:R49–R66. Published 4 February 2026. doi:10.1093/ejendo/lvag034. PubMed ↩